AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 182 min read$AQST

Barber Daniel sold $107K of AQST

Barber Daniel (President and CEO) sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at $4.29 ($0.11M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barber Daniel
Published Aug 18, 2026, 8:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AQST
Neutral
medium confidence
Mentioned
$AQST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

A CEO open-market sale under a 10b5-1 plan is typically a low-signal event for fundamentals, but it can influence short-term sentiment and positioning.

02

Market read

Traders may note the new insider-sale print, but there is no accompanying company-specific operational or financial catalyst in the text.

03

What to watch

The article does not state tax, diversification, or whether additional insider transactions occurred around the same period.

Relevance 3/10Novelty 4/10Timing: Filed 2026-08-18 after-hours; sale executed 2026-08-17.

Background

The article is a Form 4 insider transaction disclosure for Aquestive Therapeutics, Inc. (AQST).

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

Aquestive Therapeutics CEO Barber Daniel sold 25,000 shares in an open-market transaction at $4.2867 on 2026-08-17.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

Form 4 provides a fresh, time-stamped sale size and price, but the article does not include earnings, guidance, clinical, or regulatory catalysts.

Market effects

Sector

No sector-wide read-through is provided beyond a single biotech insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity management under a pre-arranged 10b5-1 plan, reducing signal value.

Key entities

  • issuer
    Aquestive Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Barber Daniel

    President and CEO who sold 25,000 shares.

  • trading_mechanism
    10b5-1 plan

    Pre-arranged plan noted as Yes in the filing.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AQST insider trading history →

Related articles

AUG 19
$AQSTMed

Aquestive (AQST) Q2 2026 Earnings Call Transcript

Aquestive (AQST) reported progress in its Anaphylm resubmission to the FDA, addressing previous issues with packaging and administration. The company's recent studies showed significant improvements in ease of use and effectiveness. Aquestive aims to resubmit Anaphylm before the end of the quarter and believes the product has a strong market opportunity, potentially exceeding $1 billion annually, due to its clinical differentiation and ease of use.

yahoo.com7 min
AUG 12
$AQSTMed

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (NASDAQ:AQST) reported Q2 revenue of $13.8M, up 38% year over year, and a net loss of $22.9M ($0.18/share). Excluding a $11.7M debt-extinguishment loss, net loss was $11.2M. The company discussed FDA resubmission review timing for Anaphylm, cash of $98.5M, and maintained 2026 guidance of $46M to $50M revenue.

yahoo.com7 min
AUG 11
$AQSTMed

Aquestive Therapeutics, Inc. (AQST): Results of Operations and Financial Condition

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film • Remains on track to resubmit Anaphyl

SEC EDGAR 8-K4 min
AUG 10
$AQSTMedAI 8/10

Why is Aquestive Therapeutics stock surging today?

Aquestive Therapeutics (AQST) shares rose about 9.4% pre-open after the company reported positive topline results from two pivotal studies for its Anaphylm (dibutepinephrine) sublingual film. The data address FDA concerns from a January 2026 Complete Response Letter and the company said its NDA resubmission remains on track for Q3 2026.

investing.com3 min
AUG 10
$AQSTMed

Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026

Aquestive Therapeutics (AQST) reported positive human factors and PK topline results for Anaphylm, including faster median pouch open time (17s to 3s) and fewer opening and placement errors. PK Cmax was comparable vs clinician dosing (391.7 vs 357.6 pg/mL) with median Tmax 12 min. No serious adverse events were reported. Aquestive plans to resubmit the NDA in Q3 2026.

tradingview.com1 min